neurology
MGFA Clinical Classification for Myasthenia Gravis
Myasthenia Gravis Foundation of America (MGFA) clinical classification for myasthenia gravis. Guides prognosis and treatment intensity. Distinguishes ocular from generalised MG.
References
- Jaretzki A et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16–23.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Pyridostigmine · Acetylcholinesterase Inhibitor — Myasthenia Gravis
- Cisatracurium · Neuromuscular Blocking Agent (Non-Depolarising)
- Atracurium · Non-Depolarising Neuromuscular Blocking Agent
- Sugammadex · Selective Neuromuscular Blockade Reversal Agent
- Suxamethonium (Anaesthesia/RSI) · Depolarising Neuromuscular Blocking Agent
- Rocuronium (Anaesthesia/RSI) · Non-Depolarising Neuromuscular Blocking Agent
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.